CDDOM Oneome Rightmed Depression Study

NAUnknownINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2023

Conditions
Depression, Anxiety
Interventions
GENETIC

Oneome RightMEd Pharmacogenomic testing Kit

The RightMed test is an end-to-end solution which includes sample collection, pharmacogenomic (PGx) testing services, data analysis, and clinical interpretation that helps physicians select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on Food and Drug Administration (FDA) medication labels. The OneOme RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1.) Green - use as directed; 2.) Yellow - use with caution; and 3.) Red - adjust dose or choose alternative mediation and can be used proactively or reactively

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OneOme, LLC

INDUSTRY

lead

University of Arizona

OTHER

NCT04909749 - CDDOM Oneome Rightmed Depression Study | Biotech Hunter | Biotech Hunter